Polygenic Risk Score Improves Prostate Cancer Risk Prediction: Results from the Stockholm-1 Cohort Study
|
|
- Susan Hancock
- 5 years ago
- Views:
Transcription
1 EUROPEAN UROLOGY 60 (2011) available at journal homepage: Platinum Priority Prostate Cancer Editorial by Anders Bjartell on pp of this issue Polygenic Risk Score Improves Prostate Cancer Risk Prediction: Results from the Stockholm-1 Cohort Study Markus Aly a,b, Fredrik Wiklund a, Jianfeng Xu c,d, William B. Isaacs e, Martin Eklund a, Mauro D Amato f, Jan Adolfsson g, Henrik Grönberg a, * a Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden b Division of Urology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden c Centre for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA d Centre for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA e The Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA f Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden g Oncological Centre, CLINTEC, Karolinska Institute, Stockholm, Sweden Article info Article history: Accepted January 8, 2011 Published online ahead of print on January 18, 2011 Keywords: Diagnosis Prostate cancer Polygenic Prediction model SNP Please visit europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically. Abstract Background: More than 1 million prostate biopsies are conducted yearly in the United States. The low specificity of prostate-specific antigen (PSA) results in diagnostic biopsies in men without prostate cancer (PCa). Additional information, such as genetic markers, could be used to avoid unnecessary biopsies. Objective: To determine whether single nucleotide polymorphisms (SNPs) associated with PCa can be used to determine whether biopsy of the prostate is necessary. Design, settings, and participants: The Stockholm-1 cohort (n = 5241) consisted of men who underwent a prostate biopsy during 2005 to PSA levels were retrieved from databases and family histories were obtained using a questionnaire. Thirty-five validated SNPs were analysed and converted into a genetic risk score that was implemented in a risk-prediction model. Results and limitations: When comparing the nongenetic model (based on age, PSA, free-to-total PSA, and family history) with the genetic model and using a fixed number of detected PCa cases, it was found that the genetic model required significantly fewer biopsies than the nongenetic model, with 480 biopsies (22.7%) avoided, at a cost of missing a PCa diagnosis in 3% of patients characterised as having an aggressive disease. However, the overall genetic model does not discriminate between aggressive and nonaggressive cases. Conclusion: Although the genetic model reduced the number of biopsies more than the nongenetic model, the clinical significance of this finding requires further evaluation. # 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, PO Box 281, SE Stockholm, Sweden Tel ; Fax: address: Henrik.Gronberg@ki.se (H. Grönberg) /$ see back matter # 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eururo
2 22 EUROPEAN UROLOGY 60 (2011) Introduction One major concern in the management of prostate cancer (PCa) is related to the overdiagnosis and subsequent overtreatment of the disease. Approximately 1 million biopsies are performed yearly in the United States, resulting in new cases being diagnosed [1]. To decrease the number of unnecessary biopsies, prediction models with better specificity are needed to guide the clinician whether or not to recommend a biopsy of the prostate. The majority of newly diagnosed patients will have undergone an ultrasound-guided prostate biopsy based on the presence of a prostate-specific antigen (PSA) level >3 4 ng/ml [2]. For values between 3 and 10 ng/ml, men have an estimated 20 25% risk of being diagnosed with PCa, although the majority of these men will not be diagnosed with the disease following an invasive examination [3]. New markers and predictive models, which can increase the test specificity, are therefore needed to reduce the number of unnecessary biopsies and eventually the number of men diagnosed with low-grade cancers. In recent years, genome-wide association studies have been instrumental in identifying common genetic variants associated with complex diseases. PCa is no exception, with 36 validated genetic variants in 29 different chromosomal loci associated with disease risk. In PCa, the odds ratio (OR) associated with risk alleles varies from 1.1 to 1.6, with the majority at the lower end of the spectrum [4 15]. Due to these small increases in risk, several researchers have questioned the clinical utility of the genetic markers. However, in PCa, we have shown that the risk of disease accumulates with the increasing number of inherited risk alleles [16]. 2. Patients and methods 2.1. Study population From patient registries in two out of three pathology departments in Stockholm, Sweden, we identified 8088 men who had undergone at least one prostate biopsy between 1 January 2005 and 31 December 2007, representing 75% of all prostate biopsies conducted during this time period in Stockholm. We excluded men older than 80 yr at the time of biopsy (n = 468), men with no valid Swedish personal identification number [17] or with no valid address (n = 78), and men deceased at the time of study invitation (n = 343). Men with known PCa before 2005 were also excluded (n = 154), as were men with cancer other than adenocarcinoma detected upon prostate biopsy (n = 10). In total, we invited 7035 men to participate in the study. The invitation included a questionnaire regarding family history of PCa. We received complete questionnaire data, written consent, and a blood sample from 5241 men (response rate: 75%) (Fig. 1). By linking the study subjects to the laboratory databases in Stockholm, we retrieved historical PSA values. We chose the PSA value closest in time to the date of biopsy, excluding values taken >130 d before. The different laboratories had different routines regarding saving results, which explains why there were more missing data on free PSA levels. For information on cancer status, we linked the study participants to the Regional Cancer Registry and to the Stockholm part of the National Prostate Cancer Registry (NPCR); information on tumour stage (TNM) and grade (Gleason score) were obtained. All men diagnosed with PCa during 2005 and 2007 at the first known biopsy were classified as biopsy positive (n = 2135), and those with a noncancer diagnosis at the first known biopsy were defined as biopsy negative (n = 3106). Aggressive PCa was defined as T3-4 N1 M1 or Gleason and higher; nonaggressive PCa was defined as T0-2 N 0/X M 0/X or Gleason and lower. Men with PSA >10 ng/ml were not included in the analysis concerning avoided prostate biopsies because they most likely would undergo biopsy anyway. The local ethics committee in Stockholm approved the study Single nucleotide polymorphism selection We selected all published PCa-associated single nucleotide polymorphisms (SNPs; up to October 2009) reported and validated in at least one independent study population. We identified 36 SNPs in 29 chromosomal loci. Multiple SNPs have been reported in the chromosomal region 8q24. We selected eight independent SNPs from this region based on the publication of Al Olama et al [4]. The SNP rs in the 8q24 region was not included in the genotype design and was thus substituted for the proxy SNP rs [11] Genotyping Markers were genotyped using matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass spectrometry based on allele-specific primer extension with the iplex chemistry (SEQUENOM Inc, San Diego, CA, USA). Hardy-Weinberg calculations were performed to verify that each marker was within an allelic equilibrium in the control population. Thirty-six SNPs were genotyped in the entire sample with a 98.6% average success rate, excluding rs on chromosome 3p12, which failed completely Statistical analysis All SNPs were tested for deviation from Hardy-Weinberg s equilibrium using a permutation-based chi-square test. We assessed associations between each SNP and PCa at biopsy using a Cochran-Armitage trend test. Allelic ORs with 95% confidence intervals were computed using logistic regression models. For each man, a genetic risk score was created by summing the number of risk alleles (0,1, or 2) at each of the 35 SNPs multiplied by the logarithm of that SNP s OR. Associations between PCa diagnosis and evaluated risk factors were explored in logistic regression analysis. Two prediction models were built to determine whether the genetic risk score could improve the prediction of PCa diagnosis: The nongenetic model included logarithmically transformed total PSA, the logarithmically transformed free-to-total PSA ratio, age at biopsy, and family history of PCa (yes or no); the genetic model also included the genetic risk score. A repeated 10-fold cross-validation was used to estimate the predicted probabilities of PCa at biopsy [18]. The genetic risk score was recalculated for each iteration of the cross-validation to preserve the independence between training and test sets, thus avoiding introducing a bias into the models predictive performance. The genetic model was compared with the nongenetic model in terms of (1) model fit, by likelihood ratio testing; (2) specificity, by the nonevents term of the net reclassification improvement (NRI) [19]; and (3) predictive performance, by using the cross-validated predicted probabilities to calculate the area under the receiver operating characteristic curves (AUC). Ninety-five percent confidence intervals for the AUC values were constructed using a normal approximation [20]. All reported p values are based on two-sided hypotheses. By assuming a polygenic model and that the sibling relative risk of PCa is 2.5 [21], and by retracing the calculations in Pharoah et al [22], the predictive performance of a hypothetic genetic model can be estimated. This optimal genetic model includes a score variable constructed from SNPs explaining 100% of the population genetic risk and thus represents
3 [()TD$FIG] EUROPEAN UROLOGY 60 (2011) men underwent biopsy of the prostate between 2005 and 2007intheareaof Stockholm, Sweden 1053 were excluded due to: Age above 80 at time of first biopsy (n = 468) Deceased at time of inclusion (n = 343) No valid Swedish personal number or valid adress (n =78) Other cancer than prostate cancer found at biopsy (n = 10) Known prostate cancer before 2005 (n =154) 7035 men invited 1794 declined participation (25.5%) 5241 men included in the cohort (74.5%) 2135 positive for prostate cancer on first known biopsy 3108 negative for prostate cancer on first known biopsy Fig. 1 Enrolment and exclusion of participants of the Stockholm-1 study. the optimal discrimination that can be obtained by adding genetic information to the prediction model. 3. Results The basic characteristics of the study participants are summarised in Table 1. We successfully genotyped 5239 of the 5241 men initially included in the study. The overall results from the 35 SNPs are summarised in Table 2.In21of 35 SNPs, the initial reported finding was confirmed ( p < 0.05). The strongest associations were observed on chromosome 8q24 rs (OR: 1.40; p < ); chromosome 19q13 rs (OR: 1.31; p < ); chromosome 22q13 rs (OR: 0.84; p < ); and chromosome 2q31 rs (OR: 0.68; p < ). In further tests we restricted our analysis to men with PSA 10 ng/ml since there is less debate over recommending a prostate biopsy in men with a PSA >10 ng/ml, at least in cases where curative treatment is an option. We analysed the 2542 men with PSA 10 ng/ml and completed the data on all variables (PSA, free-to-total PSA, age, family history, and genetic score). Although all risk factors were significantly associated with a positive biopsy (Table 3), the strongest association was recorded for the combined genetic score ( p < ). The predictive performance of the individual variables varied from an AUC for a positive family history of 52.0%, to 61.3% for the combined genetic score. When using the nongenetic model (ie, when combining all variables except the genetic score), the AUC increased significantly from 55.0% for PSA only, to 64.2% (Fig. 2a). By using the genetic model, the AUC was significantly improved to 67.4% ( p = 0.014). The genetic model had a significantly better model fit compared with the nongenetic model (likelihood ratio test, p < ). Moreover, and most important, the genetic model had a significantly higher specificity (nonevents term of NRI, p < ); that is, it avoided significantly more biopsies than the nongenetic model for a given percentage of detected cancer. For comparison purposes, Fig. 2a also shows the results for the hypothetic genetic models (ie, if all risk SNPs were known). Fig. 2c shows the relationship between percentage of detected cancer and percentage of saved biopsies for the nongenetic and the genetic models. So far, no validated SNPs have been shown to be associated with aggressive disease rather than indolent disease. This also was the case in this study, as shown in Fig. 2b, which illustrates that the discrimination between indolent and aggressive disease is not significantly better for the genetic
4 24 EUROPEAN UROLOGY 60 (2011) Table 1 Number of biopsy-positive and -negative subjects and their clinical characteristics in the Stockholm-1 study Characteristics Positive first biopsy (n = 2135) Negative first biopsy (n = 3106) PSA 10 ng/ml All PSA 10 ng/ml All Subjects, No Mean age, yr (sd) 65.0 (6.7) 66.0 (6.9) 63.7 (6.7) 64.2 (6.8) Mean PSA, ng/ml (sd) 5.9 (2.1) 21.9 (141.1) 5.49 (2.2) 7.40 (6.6) Missing data (%) 1 (0.07) 109 (5.1) 1 (0.04) 230 (7.4) Mean f/t PSA (sd) 0.15 (0.07) 0.14 (0.07) 0.18 (0.09) 0.18 (0.09) Missing f/t PSA data (%) 348 (25.6) 696 (32.6) 637 (26.2) 1014 (32.6) PSA level, ng/ml (%) (19.4) 263 (12.3) 639 (26.3) 639 (20.6) > (80.6) 1095 (51.3) 1792 (73.7) 1792 (57.7) > (17.9) 342 (11.0) > (13.3) 103 (3.3) Missing data (%) 1 (0.07) 109 (5.1) 1 (0.04) 230 (7.4) F/t PSA level, No. (%) (13.2) 364 (17.0) 180 (7.4) 238 (7.7) (43.9) 799 (37.4) 991 (40.7) 1144 (36.8) > (173) 276 (12.9) 624 (25.7) 710 (22.9) Missing data (%) 348 (25.6) 696 (32.6) 637 (26.2) 1014 (32.5) Family history of prostate cancer (%) Yes 399 (29.4) 620 (29.0) 545 (22.4) 679 (21.9) No 958 (70.5) 1511 (70.8) 1884 (77.5) 2422 (78.0) Missing data (%) 2 (0.1) 4 (0.2) 3 (0.1) 5 (0.2) Tumor stage (%) T0, T1, Tx 683 (50.3) 935 (43.8) NA T2 356 (26.2) 567 (26.6) NA T3 95 (7.0) 245 (11.5) NA T4 0 (0) 6 (0.2) NA Missing data 225(16.5) 382 (17.9) NA Nodal stage (%) N0/X 1103 (81.2) 1685 (78.9) NA N1 4 (0.3) 30 (1.4) NA Missing data 252 (18.4) 420 (19.7) NA Metastasis stage (%) M0/X 1103 (81.2) 1688 (79.1) NA M1 3 (0.2) 28 (1.3) NA Missing data 253 (18.6) 419 (19.6) NA Gleason score (%) 5 87 (6.4) 118 (5.5) NA (46.4) 822 (38.5) NA = (19.4) 440 (20.6) NA = (8.2) 208 (9.7) NA 8 40 (2.9) 118 (5.5) NA 9 18 (1.3) 76 (3.6) NA Missing data 207 (15.2) 353 (16.5) NA PSA = prostate-specific antigen; sd = standard deviation; f/t = free-to-total; NA = not applicable. model compared with the nongenetic model ( p = 0.83 when testing for AUC improvement). In a clinical setting it is relevant to study the models performance at different risk cut-off points. Using the nongenetic model and a 25% estimated risk cut-off point, 256 biopsies (10.0%) would be saved. Of these 256 biopsies, 185 (72%) were negative and 71 (28%) were positive. However, using this strategy, 8 (5%) of the aggressive cases would be missed and the men who would not be recommended a biopsy would have a 3% risk (8 of 256 cases) of having an aggressive cancer at biopsy. Using a 20% cut-off point, the number of missed aggressive cases would decrease to 2 of 143 (1%), but at the cost of doing an additional 166 biopsies. Adding the genetic score substantially improved the model, and the number of avoided biopsies increased. Using the 25% cut-off point, 480 biopsies were avoided (22.7%), 392 men were biopsy negative (82%), and 88 were biopsy positive (18%). The problem with missing aggressive cancer cases was similar to the situation without the genetic score, with 14 missed cases (9%) and a 14 in 480 cases (3%) risk of having an aggressive cancer. A 20% cut-off point would decrease the number of missed aggressive cancers substantially from 14 to 3 cases at a cost of 267 additional biopsies. If all PCa-risk SNPs were known, the hypothetic genetic model would, at a 20% risk cut-off point, save 25.5% of the biopsies. The cost of this would be that roughly 2% of the aggressive cancers would be missed (Table 4). 4. Discussion In this large population-based study, we showed that adding a genetic score based on 35 SNPs significantly improved the specificity of the prediction model for prostate biopsies compared to models based on clinical markers used today for men with a PSA level 10 ng/ml. The AUC modestly, but significantly, increased from 0.64 to 0.67 when the genetic markers were added to the model. The clinical interpretation of this increment in the AUC is not obvious, thus we need to translate it into the number of
5 EUROPEAN UROLOGY 60 (2011) Table 2 Genotype results from the Stockholm-1 study on established, common, prostate-cancer-susceptibility alleles dbsnp No. Chromosome Gene * Risk allele y Association results in the Stockholm-1 study Risk allele frequency Relative risk per allele p value Study rs p21 THADA A E-02 Eeles et al [5] rs p15 EHBP1 A E-03 Gudmundsson et al [8] rs q31.1 ITGA6 A E-05 Eeles et al [5] rs q21.3 EEFSEC A E-01 Gudmundsson et al [7] rs q22.3 PDLIM5 A E-01 Eeles et al [5] rs q22.3 PDLIM5 C E-01 Eeles et al [5] rs q24 FLJ20032 C E-03 Eeles et al [5] rs q25.3 SLC22A3 T E-01 Eeles et al [6] rs p15.2 JAZF1 G E-02 Thomas et al [9] rs q21.3 LMTK2 C E-01 Eeles et al [6] rs p21.2 NKX3-1 T E-01 Eeles et al [5] rs q24.21 C E-01 Al Olama et al [4] rs q24.21 T E-02 Al Olama et al [4] rs q24.21 T E-02 Al Olama et al [4] rs q24.21 A E-02 Al Olama et al [4] rs q24.21 C E-03 Al Olama et al [4] rs q24.21 A E-03 Gudmundsson et al [15] rs q24.21 G E-02 Gudmundsson et al [7] rs q24.21 T E-01 Gudmundsson et al [7] rs q24.21 C E-01 Al Olama et al [4] rs q24.21 G E-06 Al Olama et al [4] rs q24.21 A E-09 Amundadottir et al [11] rs q11.23 MSMB T E-04 Eeles et al [6] rs q26.13 CTBP2 C E-01 Thomas et al [9] rs p15.5 A E-03 Eeles et al [5] rs q13.2 A E-01 Zheng et al [10] rs q13.2 A E-01 Gudmundsson et al [7] rs q13.2 G E-02 Thomas et al [9] rs q12 HNF1B G E-02 Sun et al [13] rs q12 HNF1B A E-04 Gudmundsson et al [12] rs q24.3 G E-03 Gudmundsson et al [12] rs q13.2 PPP1R14A C E-03 Gudmundsson et al [7] rs q13.33 KLK3 A E-05 Eeles et al [6] rs q13.1 TNRC6B C E-01 Sun et al [14] rs q13.2 BIK G E-05 Eeles et al [5] rs Xp11.22 NUDT11 C E-05 Eeles et al [6] THADA = thyroid adenoma-associated isoform 1; EHBP1 = EH domain-binding protein 1; ITGA6 = integrin alpha chain 6; EEFSEC = elongation factor for selenoprotein translation; PDLIM5 = PDZ and LIM domain 5 isoform d; FLJ20032 = hypothetic protein LOC54790; SLC22A3 = solute-carrier family 22 member3; JAZF1 = juxtaposed with another zinc finger gene 1; LMTK2 = lemur tyrosine kinase 2; SLC25A37 = mitochondrial solute-carrier protein; NKX3-1 = NK3 transcription factor-related locus 1; MSMB = beta-microseminoprotein isoform a precursor; CTBP2 = C-terminal binding protein 2 isoform 2; HFN1B = hepatocyte nuclear factor 1 homeobox B; PPP1R14A = protein phosphatase 1 regulatory inhibitor; KLK3 = prostate-specific antigen isoform 6; TNRC6B = trinucleotide repeat containing 6B isoform 2; BIK = BCL2-interacting killer; NUDT11 = nudix-type motif 11. * These genes are within the linkage-disequilibrium block defined by the associated variant. y Risk alleles as defined from published data cited in the table. Table 3 Univariate and multivariate logistic regression of the risk factors for all cancers among men (n = 2542) with prostate-specific antigen (PSA) =10 ng/ml and complete information on the risk factors (age, PSA, free-to-total PSA, family history of prostate cancer, and genetic score) Univariate Multivariate OR (95% CI) p value AUC (95% CI) OR (95% CI) p value AUC cumulative (95% CI) PSA 1.19 ( ) < ( ) 1.17 ( ) ( ) Free-to-total PSA 0.68 ( ) < ( ) 0.69 ( ) < ( ) Age 1.23 ( ) < ( ) 1.17 ( < ( ) Family history 1.20 ( ) < ( ) 1.41 ( ) ( ) Genetic score 1.93 ( ) < ( ) 1.52 ( ) < ( ) OR = odds ratio; CI = confidence interval; AUC = area under the cross-validated receiver operating characteristics curve. *Predictive performance was assessed using the AUC for individual risk factors and for the genetic model including all risk factors. AUC cumulative denotes AUC values obtained when one risk factor at the time was added to the model from PSA only to a model including all risk factors.
6 26 [()TD$FIG] EUROPEAN UROLOGY 60 (2011) Fig. 2 (a) Receiver operating characteristics (ROC) curve for the nongenetic (red), genetic (blue), and hypothetic (orange) model. (b) ROC curve for the nongenetic (red) and genetic (blue) models for discriminating between aggressive and indolent disease. A hypothetic model is not represented here since the heritability of aggressive cancer is not known. The genetic model does not discriminate between indolent and aggressive disease. (c) Relationship between percentage-saved biopsies and percentage-detected cancer when using the nongenetic model (red), the genetic model (blue), and the hypothetic genetic model (green). The results are based on men in the Stockholm-1 cohort study with prostate-specific antigen =10 ng/ml and complete information on the risk factors (n = 2542). Table 4 Biopsies conducted and cancer detected per 1000 men with a clinical prostate biopsy based on the results from the Stockholm-1 study using a cross-validated predicted risk cut-off point of 20% or 25% as the threshold for biopsy for the nongenetic model, the genetic model, and the optimal genetic model Model, % Performed Not performed % Cancer detected Cancer missed % Aggressive cancer detected Aggressive cancer missed % Nongenetic Genetic Optimal genetic * 1 * * 3 * 5
7 EUROPEAN UROLOGY 60 (2011) biopsies that could be avoided without missing aggressive PCa at different predicted levels of individual risk. Using an estimated 20% risk of PCa as the cut-off point for conducting a biopsy, approximately 12% of the biopsies would not be performed using our genetic model compared with 5% without the nongenetic model (Table 4). This improvement could be made without missing >1% of the aggressive cancers in the population. The exact cut-off point of the risk estimate can be discussed. In our study, we observed that with a risk cut-off point of 25%, the number of saved biopsies increased to 23%, but at a cost of missing almost 10% of the aggressive cases, which in most circumstances is not acceptable. In this prediction model we incorporated a genetic score based on the first 35 SNPs associated with PCa. In the near future we estimate that approximately 100 new PCa SNPs will be discovered by different international consortia and these probably will improve the model. In addition, hitherto-reported PCa-susceptibility SNPs show limited ability to distinguish between aggressive and indolent disease [23]. Markers of aggressive disease will be important to incorporate in future prediction models. Our model is based on a population-based cohort of men who underwent biopsies for suspected PCa in the Stockholm area during However, the final analysis was only based on approximately 70% of all men who underwent biopsies in Stockholm during these years due to the fact that one major health care provider was not included in the study. No significant differences were found on comparing the clinical data between the biopsy-positive cases included in our analysis to the NPCR in the Stockholm area. Most likely this means that our results are representative and referable to current biopsy populations in Sweden. However, in populations where the prevalence of a disease (percent positive biopsies) is lower, the specificity of the model will most likely improve. This is a likely scenario in countries where PSA is used more extensively than in Sweden (eg, the United States) and in PSA screening trials. Our models were based on a Caucasian population, and these models need to be validated in other ethnic groups. The introduction of personalised medicine based on SNPs has been widely discussed, and there are a number of requirements that need to be met before taking these markers into the clinic [24]. We present evidence to show that SNPs can be used in a specific and important clinical situation: the decision to perform a prostate biopsy or not. There are several advantages with using SNP markers: They are easy to analyse, stable (need to be analysed only once), and affordable. 5. Conclusions Genetic profiles based on the common genetic risk variants established to date improve the predictive accuracy of PCa diagnosis. As many more genetic risk variants are expected to be identified in the near future, the usefulness of genetic profiles is expected to increase. Large prospective clinical studies exploring the optimal use of genetic risk profiles in PCa diagnostics are highly warranted. Author contributions: Henrik Grönberg had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Aly, Grönberg, Adolfsson, Wiklund, Eklund, D amato, Isaacs, Xu. Acquisition of data: Aly, Adolfsson, Grönberg. Analysis and interpretation of data: Aly, Eklund, Wiklund, Grönberg, Adolfsson, Xu, Isaacs, D amato. Drafting of the manuscript: Aly, Wiklund, Grönberg, Eklund. Critical revision of the manuscript for important intellectual content: Aly, Adolfsson, Wiklund, Grönberg, Eklund, Xu, Isaacs, D amato. Statistical analysis: Aly, Wiklund, Eklund. Obtaining funding: Aly, Grönberg. Administrative, technical, or material support: Grönberg, Adolfsson, Aly, D amato. Supervision: Grönberg. Other (specify): None. Financial disclosures: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. Funding/Support and role of the sponsor: Swedish Research Council (grant no. K X , and ); the Swedish Cancer Foundation (grant no ); the Hedlund Foundation; the Söderberg Foundation; the Enqvist Foundation; ALF funds from the Stockholm County Council; Stiftelsen Johanna Hagstrand och Sigfrid Linnér s Minne; and Karlsson s Fund for urologic and surgical research. This study was supported by the Cancer Risk Prediction Center (CRisP; a Linneus Centre (Contract ID ) financed by the Swedish research Council. Acknowledgment statement: We thank and acknowledge all of the participants in the Stockholm-1 study. We thank Carin Cavalli-Björkman and Ami Rönnberg Karlsson for their dedicated work in the collection of data. Michael Broms is acknowledged for his skilful work with the databases. KI Biobank is acknowledged for handling the samples and for DNA extraction. Hans Wallinder at Aleris Medilab and Sven Gustafsson at Karolinska University Laboratory are thanked fortheir good cooperation in providing historical laboratory results. We thank the Stockholm Prostate Cancer Group and its representaitves in the NPCR, Magnus Törnblom and Stefan Carlsson, for the acquisition of clinical data. References [1] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, CA Cancer J Clin 2009;59: [2] Adolfsson J, Garmo H, Varenhorst E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and Scand J Urol Nephrol 2007;41: [3] Morote J, Trilla E, Esquena S, et al. The percentage of free prostaticspecific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml. Eur Urol 2002;42: [4] Al Olama AA, Kote-Jarai Z, Giles GG, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009; 41: [5] Eeles RA, Kote-Jarai Z, Al Olama AA, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009;41:
8 28 EUROPEAN UROLOGY 60 (2011) [6] Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40: [7] Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Genomewide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009;41: [8] Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008;40: [9] Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: [10] Zheng SL, Stevens VL, Wiklund F, et al. Two independent prostate cancer risk-associated loci at 11q13. Cancer Epidemiol Biomarkers Prev 2009;18: [11] Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006;38: [12] GudmundssonJ, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39: [13] Sun J, Zheng SL, Wiklund F, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008;40: [14] Sun J, Zheng SL, Wiklund F, et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res 2009;69:10 5. [15] Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39: [16] Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358: [17] Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare andmedical research. Eur J Epidemiol 2009;24: [18] Hastie T, Tibshirani R, Friedman J. The elements of statistical learning. ed 2. New York, NY: Springer; [19] Pencina MJ, D Agostino Sr RB, D Agostino Jr RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157 72, discussion [20] Newson R. Confidence intervals for rank statistics: Somers D and extensions. Stata J 2006;6: [21] Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91: [22] Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33 6. [23] Wiklund F. Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med 2010;2:45. [24] Guttmacher AE, McGuire AL, Ponder B, Stefansson K. Personalized genomic information: preparing for the future of genetic medicine. Nat Rev Genet 2010;11:161 5.
Cumulative Association of Five Genetic Variants with Prostate Cancer
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Cumulative Association of Five Genetic Variants with Prostate Cancer S. Lilly Zheng, M.D., Jielin Sun, Ph.D., Fredrik Wiklund, Ph.D.,
More informationSupplementary Figure 1. Quantile-quantile (Q-Q) plot of the log 10 p-value association results from logistic regression models for prostate cancer
Supplementary Figure 1. Quantile-quantile (Q-Q) plot of the log 10 p-value association results from logistic regression models for prostate cancer risk in stage 1 (red) and after removing any SNPs within
More informationUtility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer
Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer Robert K. Nam, 1,9 William W. Zhang, 1 John Trachtenberg, 6 Arun Seth, 2 Laurence H. Klotz, 1 Aleksandra Stanimirovic,
More informationAdditional Disclosure
Additional Disclosure The Genetics of Prostate Cancer: Clinical Implications William J. Catalona, MD Collaborator with decode genetics, Inc. Non-paid consultant with no financial interest or support Northwestern
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Hartman M, Loy EY, Ku CS, Chia KS. Molecular
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationBlood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer
Research Article Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer Cancer Prevention Research Robert J. Klein 1, Christer Halldén
More informationEUROPEAN UROLOGY 62 (2012)
EUROPEAN UROLOGY 62 (2012) 745 752 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Allison S. Glass, Matthew R. Cooperberg and
More informationA common genetic variant of 5p15.33 is associated with risk for prostate cancer in the Chinese population
A common genetic variant of 5p15.33 is associated with risk for prostate cancer in the Chinese population Q. Ren 1,3 *, B. Xu 2,3 *, S.Q. Chen 2,3 *, Y. Yang 2,3, C.Y. Wang 2,3, Y.D. Wang 2,3, X.H. Wang
More informationInfluence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort
/, Vol. 6, No. 26 Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort Yao Zhu 1,2,*, Cheng-Tao Han 1,2,*, Hai-Tao Chen 3,4,5, Fang Liu
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationSupplementary Figure 1. Principal components analysis of European ancestry in the African American, Native Hawaiian and Latino populations.
Supplementary Figure. Principal components analysis of European ancestry in the African American, Native Hawaiian and Latino populations. a Eigenvector 2.5..5.5. African Americans European Americans e
More information*These authors contributed equally to this study. Corresponding author: X.B. Jin
Racial disparities in the association between diabetes mellitus-associated polymorphic locus rs4430796 of the HNF1β gene and prostate cancer: a systematic review and meta-analysis Y.Z. Xiang 1 *, S.B.
More informationEffects of Prostate-Specific Antigen Testing on Familial Prostate Cancer Risk Estimates
DOI: 10.1093/jnci/djq265 Advance Access publication on August 19, 2010. The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org.
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationAssociation between the 8q24 rs T/G polymorphism and prostate cancer risk: a meta-analysis
Association between the 8q24 rs6983267 T/G polymorphism and prostate cancer risk: a meta-analysis H.S. Zhu 1 *, J.F. Zhang 1 *, J.D. Zhou 2, M.J. Zhang 1 and H.X. Hu 1 1 Clinical Laboratory, East Suzhou
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationUrological Oncology. Sam Ladjevardi, Anders Berglund*, Eberhard Varenhorst, Ola Bratt, Anders Widmark and Gabriel Sandblom.
Urological Oncology Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20 100 ng/ml Sam Ladjevardi, Anders Berglund*,
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.19.8311 RESEARCH ARTICLE 8q24 rs4242382 Polymorphism is a Risk Factor for Prostate Cancer among Multi-Ethnic Populations: Evidence from Clinical Detection in
More informationProstate cancer screening in men aged years (STHLM3): a prospective population-based diagnostic study
Published in The Lancet Oncology, http://dx.doi.org/10.1016/s1470-2045(15)00361-7 Prostate cancer screening in men aged 50 69 years (STHLM3): a prospective population-based diagnostic study Henrik Grönberg,
More informationCancer develops after somatic mutations overcome the multiple
Genetic variation in cancer predisposition: Mutational decay of a robust genetic control network Steven A. Frank* Department of Ecology and Evolutionary Biology, University of California, Irvine, CA 92697-2525
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationEUROPEAN UROLOGY 63 (2013)
EUROPEAN UROLOGY 63 (2013) 419 425 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Goutham Vemana and Gerald L. Andriole on pp.
More informationAssessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information
DOI: 0.09/jnci/djq88 The Author 00. Published by Oxford University Press. Advance Access publication on October 8, 00. This is an Open Access article distributed under the terms of the Creative Com mons
More informationSupplementary Figure S1A
Supplementary Figure S1A-G. LocusZoom regional association plots for the seven new cross-cancer loci that were > 1 Mb from known index SNPs. Genes up to 500 kb on either side of each new index SNP are
More informationClinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy
european urology 54 (2008) 1081 1088 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for
More informationTITLE: Genetic Association Study of Ancestry-Matched African American Prostate Cancer Cases and Controls
AD Award Number: W81XWH-07-1-0122 TITLE: Genetic Association Study of Ancestry-Matched African American Prostate Cancer Cases and Controls PRINCIPAL INVESTIGATOR: William B. Isaacs, Ph.D. CONTRACTING ORGANIZATION:
More informationHomogeneous Prostate Cancer Mortality in the Nordic Countries Over Four Decades
EUROPEAN UROLOGY 58 (2010) 427 432 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Homogeneous Prostate Cancer Mortality in the Nordic Countries Over Four Decades
More informationExternal Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome
EUROPEAN UROLOGY 58 (2010) 727 732 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer External Validation of Urinary PCA3-Based Nomograms to Individually Predict
More informationPolygenes, Risk Prediction, and Targeted Prevention of Breast Cancer
T h e n e w e ng l a nd j o u r na l o f m e dic i n e special article Polygenes, Risk Prediction, and Targeted Prevention of Breast Cancer Paul D.P. Pharoah, Ph.D., Antonis C. Antoniou, Ph.D., Douglas
More informationTITLE: Unique Genomic Alterations in Prostate Cancers in African American Men
AD Award Number: W81XWH-12-1-0046 TITLE: Unique Genomic Alterations in Prostate Cancers in African American Men PRINCIPAL INVESTIGATOR: Michael Ittmann, M.D., Ph.D. CONTRACTING ORGANIZATION: Baylor College
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationHereditary Prostate Cancer: From Gene Discovery to Clinical Implementation
Hereditary Prostate Cancer: From Gene Discovery to Clinical Implementation Kathleen A. Cooney, MD MACP Duke University School of Medicine Duke Cancer Institute (No disclosures to report) Overview Prostate
More informationGermline Genetic Variants Associated with Prostate Cancer and Potential Relevance to Clinical Practice
Germline Genetic Variants Associated with Prostate Cancer and Potential Relevance to Clinical Practice Chee Leng Goh and Rosalind Anne Eeles Abstract The inherited link of prostate cancer predisposition
More informationOverdiagnosis Issues in Population-based Cancer Screening
OVERDIAGNOSIS The Balance of Benefit, Harm, and Cost of PSA Screening Grace Hui-Ming Wu, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, Sam Li-Sheng Chen, Jean Chin-Yuan, Fann, Tony Hsiu-Hsi Chen 2018-09-11
More informationPSA & Prostate Cancer Screening
PSA & Prostate Cancer Screening DR JONATHAN REES MD MRCS MRCGP Do you think we should have a national screening programme for Prostate Cancer using PSA? YES it s an outrage, women have breast cancer screening
More informationEvidence Based Medicine
Course Goals Goals 1. Understand basic concepts of evidence based medicine (EBM) and how EBM facilitates optimal patient care. 2. Develop a basic understanding of how clinical research studies are designed
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 21 JULY 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention Trial
More informationPSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging
european urology 54 (2008) 1073 1080 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer:
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationTransdisciplinary Science
Transdisciplinary Science Context-Dependent Effects of Genome-Wide Association Study Genotypes and Macroenvironment on Time to Biochemical (Prostate Specific Antigen) Failure after Prostatectomy Cancer
More informationThe Potential of Genes and Other Markers to Inform about Risk
Research Article The Potential of Genes and Other Markers to Inform about Risk Cancer Epidemiology, Biomarkers & Prevention Margaret S. Pepe 1,2, Jessie W. Gu 1,2, and Daryl E. Morris 1,2 Abstract Background:
More informationCorrelations between the COMT gene rs4680 polymorphism and susceptibility to ovarian cancer
Correlations between the COMT gene rs4680 polymorphism and susceptibility to ovarian cancer W. Pan 1 and H. Liao 2 1 Department of Obstetrics and Gynecology, Huangshi Central Hospital of Hubei Province
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationPage 3 of 8 Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate
More informationAssociation between ERCC1 and ERCC2 polymorphisms and breast cancer risk in a Chinese population
Association between ERCC1 and ERCC2 polymorphisms and breast cancer risk in a Chinese population R. Zhao and M.F. Ying Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University,
More informationHandling Immunogenetic Data Managing and Validating HLA Data
Handling Immunogenetic Data Managing and Validating HLA Data Steven J. Mack PhD Children s Hospital Oakland Research Institute 16 th IHIW & Joint Conference Sunday 3 June, 2012 Overview 1. Master Analytical
More informationCS2220 Introduction to Computational Biology
CS2220 Introduction to Computational Biology WEEK 8: GENOME-WIDE ASSOCIATION STUDIES (GWAS) 1 Dr. Mengling FENG Institute for Infocomm Research Massachusetts Institute of Technology mfeng@mit.edu PLANS
More informationNature Genetics: doi: /ng Supplementary Figure 1
Supplementary Figure 1 Illustrative example of ptdt using height The expected value of a child s polygenic risk score (PRS) for a trait is the average of maternal and paternal PRS values. For example,
More informationThe Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial
european urology 54 (2008) 1379 1384 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia The Relationship between Prostate Inflammation and Lower Urinary
More informationGenetic risk prediction for CHD: will we ever get there or are we already there?
Genetic risk prediction for CHD: will we ever get there or are we already there? Themistocles (Tim) Assimes, MD PhD Assistant Professor of Medicine Stanford University School of Medicine WHI Investigators
More informationHRAS1 Rare Minisatellite Alleles and Breast Cancer in Australian Women Under Age Forty Years
HRAS1 Rare Minisatellite Alleles and Breast Cancer in Australian Women Under Age Forty Years Frank A. Firgaira, Ram Seshadri, Christopher R. E. McEvoy, Gillian S. Dite, Graham G. Giles, Margaret R. E.
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationDeveloping a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection
DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong
More informationConditions. Name : dummy Age/sex : xx Y /x. Lab No : xxxxxxxxx. Rep Centre : xxxxxxxxxxx Ref by : Dr. xxxxxxxxxx
Name : dummy Age/sex : xx Y /x Lab No : xxxxxxxxx Rep Centre : xxxxxxxxxxx Ref by : Dr. xxxxxxxxxx Rec. Date : xx/xx/xx Rep Date : xx/xx/xx GENETIC MAPPING FOR ONCOLOGY Conditions Melanoma Prostate Cancer
More informationAssociation of Clinical Benign Prostate Hyperplasia with Prostate Cancer Incidence and Mortality Revisited: A Nationwide Cohort Study of Men
EUROPEAN UROLOGY 60 (2011) 691 698 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Ryan P. Kopp, Stephen J. Freedland and J.
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationGENETIC VARIATION AND PROSTATE CANCER
UMEÅ UNIVERSITY MEDICAL DISSERTATIONS New series No. 1114 ISSN 0346 6612 ISBN 978 91 7264 367 3 GENETIC VARIATION AND PROSTATE CANCER Population based association studies in Sweden SARA LINDSTRÖM Umeå
More informationOriginal Article The programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with non-small cell lung cancer risk in a Chinese Han population
Int J Clin Exp Med 2014;7(12):5832-5836 www.ijcem.com /ISSN:1940-5901/IJCEM0002117 Original Article The programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with non-small cell lung cancer risk
More informationDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta GA, USA.
A More Intuitive Interpretation of the Area Under the ROC Curve A. Cecile J.W. Janssens, PhD Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta GA, USA. Corresponding
More informationThe Role of Genetic Markers in the Management of Prostate Cancer
EUROPEAN UROLOGY 62 (2012) 577 587 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Review Prostate Cancer Editorial by Zoran Culig on pp. 588 589 of this
More informationIndividualized Estimation of the Benefit of Radical Prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial
EUROPEAN UROLOGY 62 (2012) 204 209 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Massimo Lazzeri and Francesco Montorsi on
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationTITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness
AWARD NUMBER: W81XWH-13-1-0477 TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness PRINCIPAL INVESTIGATOR: Cathryn Bock CONTRACTING ORGANIZATION: Wayne State University REPORT DATE:
More informationLack of association of IL-2RA and IL-2RB polymorphisms with rheumatoid arthritis in a Han Chinese population
Lack of association of IL-2RA and IL-2RB polymorphisms with rheumatoid arthritis in a Han Chinese population J. Zhu 1 *, F. He 2 *, D.D. Zhang 2 *, J.Y. Yang 2, J. Cheng 1, R. Wu 1, B. Gong 2, X.Q. Liu
More informationTowards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time
european urology supplements 8 (2009) 97 102 available at www.sciencedirect.com journal homepage: www.europeanurology.com Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers
More informationPSA & Prostate Cancer Screening
PSA & Prostate Cancer Screening DR JONATHAN REES MD MRCS MRCGP When a thing ceases to be a subject of controversy, it ceases to be a subject of interest Do you think we should have a national screening
More informationMORE ON SNPS AND PCA. Terrence P McGarty White Paper No 119 November, 2014
MORE ON SNPS AND PCA Terrence P McGarty White Paper No 119 November, 2014 There has been a continuing focus on SNPs and Prostate Cancer. This document reviews some of this recent works and adds to what
More informationFamily History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study
JNCI J Natl Cancer Inst (2016) 108(10): djw110 doi: 10.1093/jnci/djw110 First published online July 10, 2016 Article Family History and Probability of Prostate Cancer, Differentiated by Risk Category:
More informationRESEARCH. Randomised prostate cancer screening trial: 20 year follow-up
1 CLINTEC, Karolinska Institute, 141 86 Stockholm, Sweden 2 Department of Urology, Linköping University Hospital, Linköping 3 Oncology Centre, Linköping University Hospital, Linköping 4 Department of Mathematical
More informationNIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 October 1.
NIH Public Access Author Manuscript Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 October ; 19(10): 2639 2646. doi: 10.1158/1055-9965.EPI-10-0427. A common prostate cancer risk
More informationSatisfaction and Regret after Open Retropubic or Robot- Assisted Laparoscopic Radical Prostatectomy
european urology 54 (2008) 785 793 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Satisfaction and Regret after Open Retropubic or Robot- Assisted Laparoscopic
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationNew Enhancements: GWAS Workflows with SVS
New Enhancements: GWAS Workflows with SVS August 9 th, 2017 Gabe Rudy VP Product & Engineering 20 most promising Biotech Technology Providers Top 10 Analytics Solution Providers Hype Cycle for Life sciences
More informationAssociation between interleukin-17a polymorphism and coronary artery disease susceptibility in the Chinese Han population
Association between interleukin-17a polymorphism and coronary artery disease susceptibility in the Chinese Han population G.B. Su, X.L. Guo, X.C. Liu, Q.T. Cui and C.Y. Zhou Department of Cardiothoracic
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationGenome-wide Association Analysis Applied to Asthma-Susceptibility Gene. McCaw, Z., Wu, W., Hsiao, S., McKhann, A., Tracy, S.
Genome-wide Association Analysis Applied to Asthma-Susceptibility Gene McCaw, Z., Wu, W., Hsiao, S., McKhann, A., Tracy, S. December 17, 2014 1 Introduction Asthma is a chronic respiratory disease affecting
More informationGenetic Predictors of Radiosensitivity.
Genetic Predictors of Radiosensitivity. Richard G. Stock, MD Professor, Director of Genito-Urinary Oncology Department of Radiation Oncology Ichan School of Medicine at Mount Sinai New York, NY DISCLOSURE
More informationGenetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma
Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma M.J. Wang, Y. Zhu, X.J. Guo and Z.Z. Tian Department of Orthopaedics, Xinxiang Central Hospital, Xinxiang,
More informationHorizon Scanning Technology Briefing. Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer
Horizon Scanning Technology Briefing National Horizon Scanning Centre Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer December 2006 This technology summary is based on
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationLack of association between IL-6-174G>C polymorphism and lung cancer: a metaanalysis
Lack of association between IL-6-174G>C polymorphism and lung cancer: a metaanalysis Y. Liu, X.L. Song, G.L. Zhang, A.M. Peng, P.F. Fu, P. Li, M. Tan, X. Li, M. Li and C.H. Wang Department of Respiratory
More informationGenetic Susceptibility Loci, Pesticide Exposure and Prostate Cancer Risk
Genetic Susceptibility Loci, Pesticide Exposure and Prostate Cancer Risk Stella Koutros 1 *, Sonja I. Berndt 1, Kathryn Hughes Barry 1, Gabriella Andreotti 1, Jane A. Hoppin 2, Dale P. Sandler 2, Meredith
More informationValidation of a Prostate Cancer Polygenic Risk Score for Clinical Use
Validation of a Prostate Cancer Polygenic Risk Score for Clinical Use September 2018 Mary Helen Black 1, Shuwei Li1, Holly LaDuca 1, Jefferey Chen1, Robert Hoiness1, Stephanie Gutierrez1, Brigette TippinDavis1,
More informationWhite Paper Estimating Complex Phenotype Prevalence Using Predictive Models
White Paper 23-12 Estimating Complex Phenotype Prevalence Using Predictive Models Authors: Nicholas A. Furlotte Aaron Kleinman Robin Smith David Hinds Created: September 25 th, 2015 September 25th, 2015
More informationSensitivity, specicity, ROC
Sensitivity, specicity, ROC Thomas Alexander Gerds Department of Biostatistics, University of Copenhagen 1 / 53 Epilog: disease prevalence The prevalence is the proportion of cases in the population today.
More informationbreast cancer; relative risk; risk factor; standard deviation; strength of association
American Journal of Epidemiology The Author 2015. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail:
More informationInvestigation on ERCC5 genetic polymorphisms and the development of gastric cancer in a Chinese population
Investigation on ERCC5 genetic polymorphisms and the development of gastric cancer in a Chinese population L.Q. Yang 1, Y. Zhang 2 and H.F. Sun 3 1 Department of Gastroenterology, The Second Affiliated
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationFTO Polymorphisms Are Associated with Obesity But Not with Diabetes in East Asian Populations: A Meta analysis
BIOMEDICAL AND ENVIRONMENTAL SCIENCES 22, 449 457 (2009) www.besjournal.com FTO Polymorphisms Are Associated with Obesity But Not with Diabetes in East Asian Populations: A Meta analysis BO XI #, + AND
More informationIdentification of new genetic risk factors for prostate cancer
Review Asian Journal of Andrology (2009) 11: 49 55 2009 AJA, SIMM & SJTU All rights reserved 1008-682X/09 $ 30.00 www.nature.com/aja 49 Identification of new genetic risk factors for prostate cancer Michelle
More informationSaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer
Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationIS IT GENETIC? How do genes, environment and chance interact to specify a complex trait such as intelligence?
1 IS IT GENETIC? How do genes, environment and chance interact to specify a complex trait such as intelligence? Single-gene (monogenic) traits Phenotypic variation is typically discrete (often comparing
More information2) Cases and controls were genotyped on different platforms. The comparability of the platforms should be discussed.
Reviewers' Comments: Reviewer #1 (Remarks to the Author) The manuscript titled 'Association of variations in HLA-class II and other loci with susceptibility to lung adenocarcinoma with EGFR mutation' evaluated
More informationThe Clinical Potential of Pretreatment Serum Testosterone Level to Improve the Efficiency of Prostate Cancer Screening
european urology 51 (2007) 375 380 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Clinical Potential of Pretreatment Serum Testosterone Level to Improve
More information4Kscore. A Precision Test for Risk of Aggressive Prostate Cancer
4Kscore A Precision Test for Risk of Aggressive Prostate Cancer How to Evaluate Risk for Prostate Cancer? PSA is a good screening tool But abnormal PSA leads to over 1 million prostate biopsies each year
More informationMaterials and methods. Carcinogenesis vol.28 no.6 pp , 2007 doi: /carcin/bgl242 Advance Access publication December 6, 2006
Carcinogenesis vol.28 no.6 pp.1197 1201, 2007 doi:10.1093/carcin/bgl242 Advance Access publication December 6, 2006 Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase
More informationUNIVERSITY OF CALIFORNIA, LOS ANGELES
UNIVERSITY OF CALIFORNIA, LOS ANGELES BERKELEY DAVIS IRVINE LOS ANGELES MERCED RIVERSIDE SAN DIEGO SAN FRANCISCO UCLA SANTA BARBARA SANTA CRUZ DEPARTMENT OF EPIDEMIOLOGY SCHOOL OF PUBLIC HEALTH CAMPUS
More information